SecBot SecBot
DEF 14A ·Filed Nov 9, 2026

RVPH

REVIVA PHARMACEUTICALS HOLDINGS, INC.
NEUTRAL
Impact 4/10
Horizonweeks Processed7d 10h ago SEC0001437749-26-035893
Definitive proxy statement
Actionable Insight • Neutral

Monitor whether the Board implements the reverse stock split and at what ratio, as this is a prerequisite for a potential Nasdaq uplisting. The company's ability to meet initial listing requirements and sustain compliance after any uplisting remains uncertain.

DirectionNeutral
Confidencehigh
Horizonweeks

How the stock moved after the report

NEUTRAL VIEWSTOCK AT ENTRY AT T+1
Entry
$0.3521
T+0 close · Nov 9, 2026 · via day close
Latest settled
0.00%
T+1 · $0.3521 · next T+5 in 4h
Vs SPY
−1.32%
α at T+1
Latest observation
+4.69%
T+2 · FF3 residual α
  1. T+0 · Nov 10 $0.3521entry
  2. T+1 · 6d ago 0.00%α −1.32% · $0.3521
  3. T+4 · todayOpen
  4. T+5 · in 4h Pending
  5. T+20 · in 22d Pending
  6. T+60 · in 3mo Pending

Price Chart

Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Reviva Pharmaceuticals Holdings, Inc. filed its definitive proxy statement for the 2026 Annual Meeting of Stockholders to be held on December 18, 2026. The proxy includes proposals to elect five director nominees, ratify Baker Tilly as auditor, approve executive compensation on an advisory basis, and authorize a reverse stock split of common stock at a ratio between 1:2 and 1:100, at the Board's discretion, to facilitate a potential uplisting to Nasdaq or another national exchange.

Key Facts

  • Annual Meeting scheduled for December 18, 2026, to be held virtually.
  • Five director nominees standing for election: Laxminarayan Bhat, Parag Saxena, Richard Margolin, Purav Patel, Les Funtleyder.
  • Proposal to ratify Baker Tilly US, LLP as independent auditor for fiscal year 2026.
  • Advisory Say-on-Pay vote on executive compensation.
  • Proposal to authorize a reverse stock split at a ratio ranging from 1:2 to 1:100, at the Board's discretion, prior to December 31, 2027.
  • Common stock delisted from Nasdaq on May 14, 2026; currently quoted on OTCQB under symbol RVPH.
  • As of October 30, 2026 record date, 13,110,377 shares of common stock outstanding.
  • CEO Laxminarayan Bhat total compensation for 2025: $1,442,121 (salary $565,000, bonus $110,175, option awards $766,946).
  • CFO Narayan Prabhu total compensation for 2025: $659,670 (salary $330,000, bonus $42,620, option awards $287,050).
  • Related party transaction: CEO's spouse Seema R. Bhat employed as VP, Program & Portfolio Management with 2025 base salary of $340,000.
  • 5%+ holder: Integrated Core Strategies (US) LLC beneficially owns 8.2% of common stock.
  • Chairman Parag Saxena beneficially owns 2.7% of common stock.
  • Net loss for 2025: $19,864,902; for 2024: $29,918,802; for 2023: $39,260,837.

Financial Impact

Reverse stock split authorized up to 1:100; no immediate financial impact. Net loss improved from $29.9M in 2024 to $19.9M in 2025.

share countnet loss

Risk Factors

  • Reverse split may not achieve desired stock price increase or Nasdaq uplisting.
  • Continued OTCQB trading limits liquidity and institutional investor access.
  • CEO compensation increased significantly in 2025 despite net losses.
  • Related party employment of CEO's spouse may raise governance concerns.

Market Snapshot

Exchange
OTC
Sector
Pharmaceutical Preparations
Analyst Consensus
82% bullish (11 analysts)

Investment Themes

Documents Analyzed

This report is based on 3 SEC documents filed with EDGAR.

DocumentAccession Number
DEF 14A Filing (Primary)0001437749-26-035893
Document: 0001437749-26-035893-index.html0001437749-26-035893
Document: 0001437749-26-035893.txt0001437749-26-035893

Track record

12 reports on RVPH

Performance horizon

2 of 4 bullish or bearish reports moved the stock their way by T+60. Best: +22.98% at T+20 after the Jul 10, 2026 report. 2 of 4 went positive at some point.

Filters
  1. Nov 12, 20264d ago 8-K Neutral 3/10 No price data
  2. Nov 12, 20264d ago Press Release Neutral 4/10 Entry $0.3533 Now $0.3504 −0.81% settles Feb 11
  3. Nov 9, 20267d ago DEF 14A Neutral 4/10 Viewing Entry $0.3521 Now $0.3504 −0.47% settles Feb 8
  4. Aug 12, 202613w ago Press Release Neutral 4/10 Entry $0.3521 to $0.3521 Now $0.3504 −0.47% · 0.00% +5.48% vs SPY
  5. Jul 10, 202618w ago 25-NSE Bearish 7/10 Entry $0.6200 to $0.5000 Now $0.3504 +43.48% ▲ +19.35% +22.24% vs SPY
  6. May 13, 202626w ago Press Release Bearish 7/10 Entry $0.3900 to $0.4303 Now $0.3504 +10.14% ▼ −10.33% −6.74% vs SPY
  7. May 13, 202626w ago 8-K Bearish 8/10 Entry $0.3521 to $0.4775 Now $0.3504 +0.47% ▼ −35.62% −31.19% vs SPY
  8. Apr 15, 202630w ago 8-K Neutral 5/10 Entry $0.8900 to $0.5731 Now $0.3504 −60.62% ▼ −35.61% −43.74% vs SPY
  9. Mar 30, 202633w ago Press Release Mixed 6/10 Entry $0.6600 to $0.6000 Now $0.3504 −46.90% ▼ −9.09% −25.58% vs SPY
  10. Mar 18, 202634w ago Press Release Bearish 6/10 Entry $0.8300 to $0.7000 Now $0.3504 +57.78% ▲ +15.66% +30.01% vs SPY
Showing 10 of 12

US Market Status

Market Closed · Opens in 6h 50m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Nov 9, 2026